Visual Side Effects Linked to Sildenafil Consumption: An Update

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10045/113703
Información del item - Informació de l'item - Item information
Título: Visual Side Effects Linked to Sildenafil Consumption: An Update
Autor/es: Ausó-Monreal, Eva | Gómez-Vicente, Violeta | Esquiva, Gema
Grupo/s de investigación o GITE: Grupo de Investigación en Alimentación y Nutrición (ALINUT) | Grupo de Óptica y Percepción Visual (GOPV) | Genética Humana y de Mamíferos (GHM) | Neurobiología del Sistema Visual y Terapia de Enfermedades Neurodegenerativas (NEUROVIS)
Centro, Departamento o Servicio: Universidad de Alicante. Departamento de Óptica, Farmacología y Anatomía
Palabras clave: Phosphodiesterase | Guanylyl cyclase | Viagra | Retinal toxicity
Área/s de conocimiento: Anatomía y Embriología Humana
Fecha de publicación: 12-mar-2021
Editor: MDPI
Cita bibliográfica: Ausó E, Gómez-Vicente V, Esquiva G. Visual Side Effects Linked to Sildenafil Consumption: An Update. Biomedicines. 2021; 9(3):291. https://doi.org/10.3390/biomedicines9030291
Resumen: Phosphodiesterase type 5 (PDE5) inhibitors such as Viagra® (sildenafil citrate) have demonstrated efficacy in the treatment of erectile dysfunction (ED) by inducing cyclic guanosine monophosphate (cGMP) elevation followed by vasodilation and increased blood flow. It also exerts minor inhibitory action against PDE6, which is present exclusively in rod and cone photoreceptors. The effects of sildenafil on the visual system have been investigated in a wide variety of clinical and preclinical studies due to the fact that a high dose of sildenafil may cause mild and transient visual symptoms in some patients. A literature review was performed using PubMed, Cochrane Library and Clinical Trials databases from 1990 up to 2020, focusing on the pathophysiology of visual disorders induced by sildenafil. The aim of this review was not only to gather and summarize the information available on sildenafil clinical trials (CTs), but also to spot subpopulations with increased risk of developing undesirable visual side effects. This PDE inhibitor has been associated with transient and reversible ocular side effects, including changes in color vision and light perception, blurred vision, photophobia, conjunctival hyperemia and keratitis, and alterations in the electroretinogram (ERG). Sildenafil may induce a reversible increase in intraocular pressure (IOP) and a few case reports suggest it is involved in the development of nonarteritic ischemic optic neuropathy (NAION). Reversible idiopathic serous macular detachment, central serous retinopathy and ERG disturbances have been related to the significant impact of sildenafil on retinal perfusion. So far, sildenafil does not seem to cause permanent toxic effects on chorioretinal tissue and photoreceptors as long as the therapeutic dose is not exceeded and is taken under a physician’s direction to treat a medical condition. However, the recreational use of sildenafil can lead to harmful side effects, including vision changes.
URI: http://hdl.handle.net/10045/113703
ISSN: 2227-9059
DOI: 10.3390/biomedicines9030291
Idioma: eng
Tipo: info:eu-repo/semantics/article
Derechos: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Revisión científica: si
Versión del editor: https://doi.org/10.3390/biomedicines9030291
Aparece en las colecciones:INV - GHM - Artículos de Revistas
INV - NEUROVIS - Artículos de Revistas
INV - ALINUT - Artículos de Revistas
INV - GOPV - Artículos de Revistas

Archivos en este ítem:
Archivos en este ítem:
Archivo Descripción TamañoFormato 
ThumbnailAuso_etal_2021_Biomedicines.pdf692,71 kBAdobe PDFAbrir Vista previa


Todos los documentos en RUA están protegidos por derechos de autor. Algunos derechos reservados.